Roman Chlíbek
YOU?
Author Swipe
View article: Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic
Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic Open
There is high incidence of symptomatic Bbsl infections in the Czech Republic, particularly in Moravia. Interventions are needed to address the substantial burden of LB in the Czech Republic.
View article: Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries
Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries Open
Our results indicated that two doses of varicella zoster virus-containing vaccine provided better protection than one dose against varicella and induced antibody responses that persisted 10 years post-vaccination.
View article: Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials Open
While the ZOE-50/70 studies were not powered or pre-designed for these post-hoc analyses, RZV appears efficacious against HZ and PHN irrespective of sex, region, or geographic ancestry/ethnicity.
View article: Chronic hepatitis C in the Czech Republic: Forecasting the disease burden
Chronic hepatitis C in the Czech Republic: Forecasting the disease burden Open
Disease burden associated with chronic HCV infection is projected to peak in the Czech Republic in 30-40 years. Assuming that the current portion of DAAs used remains constant, a significant reduction in HCV disease burden is possible thro…
View article: Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials Open
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ).Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomiz…
View article: Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older Open
NCT01165177; NCT01165229.
View article: Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults Open
After vaccination with HZ/su, both cell mediated and humoral immunity remained above pre-vaccination levels up to year 9 regardless of age group. Immune responses are predicted to remain above baseline up to 15 years post initial vaccinati…
View article: Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older : Results from the Efficacy Studies ZOE-50 and ZOE-70
Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older : Results from the Efficacy Studies ZOE-50 and ZOE-70 Open
Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older: Results from the Efficacy Studies ZOE-50 and ZOE-70
View article: Serological survey of mumps antibodies in adults in the Czech Republic and the need for changes to the vaccination strategy
Serological survey of mumps antibodies in adults in the Czech Republic and the need for changes to the vaccination strategy Open
Mumps outbreaks, especially in adolescents and young adults, have been reported in the Czech Republic. The aim of the presented study was to determine the seroprevalence of specific IgG antibodies against mumps in the adult population of t…
View article: Influenza vaccination in the elderly
Influenza vaccination in the elderly Open
Seasonal influenza is a prevalent and serious annual illness resulting in widespread morbidity and economic disruption throughout the population; the elderly and immunocompromised are particularly vulnerable to serious sequelae and mortali…
View article: Prevalence of hepatitis C virus in adult population in the Czech Republic – time for birth cohort screening
Prevalence of hepatitis C virus in adult population in the Czech Republic – time for birth cohort screening Open
Chronic hepatitis C is curable disease. Low detection rate could be one of the reasons of poor treatment uptake. It is important to identify HCV prevalence and anti-hepatitis C virus (HCV) positive patients in population by effective scree…
View article: Decreasing Seroprevalence of Measles Antibodies after Vaccination – Possible Gap in Measles Protection in Adults in the Czech Republic
Decreasing Seroprevalence of Measles Antibodies after Vaccination – Possible Gap in Measles Protection in Adults in the Czech Republic Open
A long term high rate of seropositivity persists after natural measles infection. By contrast, it decreases over time after vaccination. Similarly, the concentrations of antibodies in persons with measles history persist for a longer time …
View article: CHARACTERISTICS OF VARICELLA ZOSTER (VZV) VIRUS
CHARACTERISTICS OF VARICELLA ZOSTER (VZV) VIRUS Open
The evolution of varicella zoster virus lasts more than 400 million years.While primates were the original reservoirs of the virus, subsequently VZV started to circulate in human population and humans have been the exclusive hosts for VZV …
View article: Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older Open
In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT0…
View article: Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013
Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013 Open
We undertook an epidemiological survey of the annual incidence of pertussis reported from 2000 to 2013 in ten Central and Eastern European countries to ascertain whether increased pertussis reports in some countries share common underlying…
View article: Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults Open
gE-specific cellular and humoral immune responses persisted for 6 years after two-dose vaccination with HZ/su in healthy older adults. No safety concerns were identified.
View article: Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Open
The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older. Vaccine efficacy in adults who were 70 years of age or older was similar to that in the other two age groups. (Funded by GlaxoSm…